An interventional study of Glandy HYPER (AI-based monitoring software) and Methimazole in Hyperthyroidism, Graves Disease and Thyrotoxicosis, sponsored by THYROSCOPE INC.. Not yet recruiting at 2 sites in Germany. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by THYROSCOPE INC. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Graves' disease is the most common cause of hyperthyroidism and is usually treated with antithyroid drugs such as methimazole (MMI). The MMI dose is adjusted according to periodic blood tests, but individual responses vary, so some patients remain hyperthyroid longer than necessary while others become hypothyroid from overtreatment. Glandy HYPER is a CE-marked, AI-based software medical device that analyzes sleep heart rate data collected by a smartwatch, together with thyroid function test results, to provide daily information on thyrotoxicosis status. This exploratory, post-market, two-center, randomized, open-label study in Germany evaluates whether MMI dose adjustment supported by Glandy HYPER shortens the time to normalization of free T4 compared with standard care, and also assesses overtreatment, thyroid-related quality of life, and safety.
This is an exploratory, post-market, prospective, randomized, open-label, two-arm clinical study conducted at two sites in Frankfurt, Germany (protocol 01-01-DE-001). It evaluates the clinical utility, performance and safety of Glandy HYPER, a CE-marked (MDR Class IIa) AI-based software medical device, in supporting methimazole (MMI) dose adjustment in adults with newly diagnosed or persistent thyrotoxic Graves' disease.
After written informed consent at Visit 1 (screening, Day -14 to 0), participants are randomized 2:1 (intervention:control) using a computer-generated procedure in the secuTrial EDC system. All participants receive a smartwatch with a CE-certified ECG function (Apple Watch for iOS users, Samsung Galaxy Watch for Android users) and are trained in its use; they wear it during sleep (at least 3 hours) and record an ECG before bedtime. Patients already taking MMI must be able to stop it between Visit 1 and Visit 2. At Visit 2 (baseline, Day 0), participants with confirmed thyrotoxicosis (free T4) and available sleep heart rate data are registered and MMI is started. Follow-up visits take place at Weeks 4, 8 and 12 (Visits 3-5, each +/- 1 week) with routine blood tests (free T4, TSH, liver parameters, blood count); the ThyPRO-39 quality-of-life questionnaire is completed at Visits 2-5. Participation lasts approximately 14 weeks.
Intervention arm (n=20): The MMI starting dose is determined by a predefined algorithm based on the Visit 1 free T4 level relative to the upper limit of normal. Glandy HYPER provides a once-daily thyrotoxicosis status result. If a "non-hyperthyroid" result occurs on three or more occasions between scheduled visits, the treating physician decides on MMI dose adjustment based on the clinical and laboratory situation, taking the Glandy HYPER data into account, and may schedule an unscheduled visit for laboratory confirmation; an unscheduled visit replaces the next scheduled visit. At each visit, if free T4 is above the normal range, the dose follows the predefined dose criteria; if free T4 is within the normal range, the dose is determined by the physician.
Control arm (n=10): MMI is started and adjusted by the physician according to routine care. Wearable data are collected, but Glandy HYPER results are not disclosed to participants or physicians and are not used for clinical decisions.
Glandy HYPER provides decision support only, and all dose decisions are made by the treating physician. After completion of the study schedule, the performance of Glandy HYPER in detecting thyrotoxicosis is evaluated against the laboratory free T4-based thyroid status.
113 studies on the registry are indexed under Hyperthyroidism; 28 are open to participants now.
This study's planned enrollment of 30 is below the median of 60 across 61 interventional studies indexed under Hyperthyroidism.
Browse Hyperthyroidism studies →THYROSCOPE INC. is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants wear a smartwatch and use the Glandy HYPER app, which provides a once-daily thyrotoxicosis status result based on sleep heart rate data. Methimazole (MMI) is started at Visit 2 at a dose determined by a predefined algorithm based on the Visit 1 free T4 level. If a "non-hyperthyroid" result occurs on three or more occasions between scheduled visits, the treating physician decides on MMI dose adjustment based on the clinical and laboratory situation, taking the Glandy HYPER data into account, and may schedule an unscheduled visit for laboratory confirmation. All dose decisions are made by the treating physician.
Device: Glandy HYPER (AI-based monitoring software) · Drug: Methimazole
Participants wear the same smartwatch; wearable data are collected, but Glandy HYPER results are not disclosed to participants or physicians and are not used for clinical decisions. Methimazole (MMI) is started at Visit 2 and adjusted by the physician according to routine clinical care based on blood tests at scheduled visits (every 4 weeks +/- 1 week); the visit interval may be shortened at the physician's discretion.
Drug: Methimazole
CE-marked (MDR Class IIa) software as a medical device (mobile app) that analyzes sleep heart rate data collected by a smartwatch, together with thyroid function test results (free T4, TSH), to provide information on thyrotoxicosis status. In the intervention arm, the once-daily results are available to the treating physician to support methimazole dose adjustment.
Oral antithyroid drug for the treatment of hyperthyroidism. Intervention arm: starting dose per a predefined free T4-based algorithm; subsequent adjustments are decided by the treating physician taking Glandy HYPER results into account. Control arm: starting dose and adjustments per the physician's routine clinical judgment.
Time to First Normal Free T4 Level
Time (days) from initiation of antithyroid medication (methimazole) at Visit 2 to the first laboratory confirmation of a serum free T4 (fT4) level within the site-specific normal range (Site 1: 0.82-1.77 ng/dL; Site 2: 0.93-1.67 ng/dL), assessed at scheduled and unscheduled clinic visits and compared between the intervention and control arms.
Time frame: From Visit 2 (Day 0) to Visit 5 (Week 12 +/- 1 week)
Number of Occurrences of Free T4 Below the Lower Limit of Normal
Number of clinic visits (scheduled or unscheduled) per participant at which serum free T4 is below the site-specific lower limit of normal (Site 1: \<0.82 ng/dL; Site 2: \<0.93 ng/dL), as an indicator of overtreatment (iatrogenic hypothyroidism).
Time frame: From Visit 2 (Day 0) to Visit 5 (Week 12 +/- 1 week)
Change From Baseline in Thyroid-Related Quality of Life (ThyPRO-39)
Thyroid-related quality of life is assessed with the self-administered ThyPRO-39 questionnaire (Thyroid-Related Patient-Reported Outcome, 39-item short version) at each clinic visit. Scale scores, including the composite quality-of-life impact score, range from 0 to 100, with higher scores indicating worse quality of life. Scores at each visit and change from baseline (Visit 2) are reported.
Time frame: Baseline (Visit 2, Day 0), Week 4 (Visit 3), Week 8 (Visit 4) and Week 12 (Visit 5); visits +/- 1 week
Number of Participants With Procedure-Related Serious Incidents
Serious incidents (as defined in Regulation (EU) 2017/745) assessed by the investigator as related to the study device or study procedures, coded using IMDRF terminology.
Time frame: From informed consent (Visit 1) to Visit 5 (Week 12 +/- 1 week)
Diagnostic Performance of Glandy HYPER for Detecting Thyrotoxicosis
Agreement between the Glandy HYPER output (thyrotoxic vs. non-thyrotoxic) and the thyroid status determined by laboratory free T4 (site-specific reference ranges) at each clinic visit with a blood test, expressed as sensitivity, specificity, positive predictive value and negative predictive value with 95% confidence intervals, pooled across both arms. Evaluated after completion of the study schedule.
Time frame: At each clinic visit with a blood test from Visit 3 (Week 4) to Visit 5 (Week 12 +/- 1 week)
Plan to share: No — No individual participant data will be shared. The final clinical study report (with personal data redacted) and a lay summary will be made publicly available on ClinicalTrials.gov.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.
Of 15 interventional studies with no phase under Hyperthyroidism, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 46. This study's planned 8 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.